{
  "abstract": "Anaemia is a frequent and clinically relevant complication of systemic lupus erythematosus (SLE), particularly in patients with lupus nephritis (LN), where systemic inflammation, impaired iron utilisation, immune-mediated mechanisms, treatment toxicity and kidney dysfunction may coexist.1 Treatment of anaemia in SLE/LN is not well established and relies on correcting reversible causes and controlling inflammatory activity. However, anaemia can persist despite control of SLE activity, creating a therapeutic challenge.2",
  "authors": [
    {
      "affiliations": [
        "Internal Medicine, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain"
      ],
      "name": "Mario Martín-Portugués"
    },
    {
      "affiliations": [
        "Internal Medicine, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain",
        "UNIR Health Sciences School & Medical Center, UNIR, Logroño, Spain"
      ],
      "name": "Victor Moreno-Torres"
    },
    {
      "affiliations": [
        "Internal Medicine, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain"
      ],
      "name": "Pedro Durán-del Campo"
    },
    {
      "affiliations": [
        "Nephrology, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain"
      ],
      "name": "Lucía Martín- Tesillano"
    },
    {
      "affiliations": [
        "Nephrology, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain"
      ],
      "name": "José Portoles"
    },
    {
      "affiliations": [
        "Nephrology, Puerta de Hierro University Hospital of Majadahonda, Majadahonda, Spain"
      ],
      "name": "Ana Huerta"
    }
  ],
  "title": "Roxadustat in lupus nephritis: a novel therapeutic signal for multifactorial anaemia",
  "uid": "c4049f89-81a1-58d5-9638-b702835295a3"
}